Compare AstraZeneca plc (AZN) vs KeyCorp (KEY) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

KeyCorp (KEY) trades at $23.22, down 0.34% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and a net income margin of 26.05% for 2025. Analyst consensus is heavily bullish with a $29.32 price target, and recent news highlights partnerships and a new $3 billion buyback program.

The outlook for KEY is positive, driven by earnings beats, robust capital returns, and improving profitability. Risks include volatile cash flows and macroeconomic sensitivity, but institutional support and a low P/E of 14.25 suggest undervaluation, offering potential upside for investors seeking regional bank exposure.